vh4524184 + rifabutin

VH4524184 + rifabutin is a **combination of two antiretroviral agents**: - **VH4524184 (VH-184)** is an investigational, third-generation integrase strand transfer inhibitor (INSTI) with long-acting potential, developed as part of novel HIV-1 therapy regimens. VH4524184 exhibits a high barrier to resistance and retains strong antiviral activity even against viruses with mutations associated with resistance to second-generation INSTIs. Its mechanism is the inhibition of the HIV-1 integrase enzyme, blocking viral DNA integration and thus suppressing viral replication. Early phase clinical data show favorable safety, tolerability, and pharmacokinetic characteristics, as well as potential for both oral and injectable administration. - **Rifabutin** is an established antibacterial from the rifamycin class, acting as an inhibitor of bacterial DNA-dependent RNA polymerase and used primarily in tuberculosis (especially mycobacterial infection) management, including HIV-associated mycobacterial co-infection. In the context of HIV, rifabutin is considered for use due to its less pronounced effect on cytochrome P450-mediated drug-drug interactions compared to related rifamycins. This combination is anticipated for use in **HIV-1 infection**, likely targeting populations with or at risk for mycobacterial co-infection, although published clinical trial data for this exact combination (VH4524184 + rifabutin) is not directly available. The primary component, VH4524184, is currently in early clinical trial phases for HIV-1, while rifabutin is approved and in global use for mycobacterial infections, including in people living with HIV[1][2][3][4][5].